Registry data provide real-world information on treatment effectiveness.
Few randomized, controlled trials have been conducted to test treatments for the various forms of autoimmune encephalitis (AE). Investigators have now evaluated outcomes when rituximab was used in 149 patients with AE, compared to not being used in 163 patients, in the GENERATE registry from Germany, Austria, and Switzerland. AE etiologies including N-methyl-D-aspartate receptor (NMDAR), contactin-associated protein-like 2 (CASPR2), leucine-rich glioma-inactivated 1 (LGI1), and glutamic acid decarboxylase 65 (GAD65).
Most patients and all rituximab recipients had first-line immunotherapy with corticosteroids, plasma exchange/immunoabsorption, intravenous immunoglobulin, or a combination of these. Median time to rituximab use was 54 days for …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)